Vaxart (STU:NB11) Institutional Ownership : 8.44% (As of Jun. 21, 2024)

View and export this data going back to . Start your Free Trial

What is Vaxart Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Vaxart's institutional ownership is 8.44%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Vaxart's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Vaxart's Float Percentage Of Total Shares Outstanding is 98.93%.

Vaxart Institutional Ownership Historical Data

The historical data trend for Vaxart's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxart Institutional Ownership Chart

Vaxart Historical Data

The historical data trend for Vaxart can be seen below:

	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30	2024-05-31
Institutional Ownership	11.52	11.24	8.59	8.65	8.59	7.90	7.93	8.59	8.43	8.43

Vaxart Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Vaxart (STU:NB11) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxart Inc (STU:NB11) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

VXRT:USA VXRT:Mexico

Address

170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.vaxart.com

Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

Vaxart (STU:NB11) Headlines

No Headlines